<2> New Weight Loss Pill Outperforms Oral Semaglutide for Diabetes Patients, Study Reports
<3> Orforglipron: A New Treatment Option for Type 2 Diabetes
<4> Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, has been reported to lead to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), according to a recent study.1 The study, published in the Lancet, suggests that orforglipron could be a new treatment option for people with type 2 diabetes who prefer to take a pill rather than receive an injection.
<5> Current Treatment Options for Type 2 Diabetes
Currently, semaglutide—the only available oral GLP-1 drug—is available in pill form, but it must be taken on an empty stomach. Orforglipron, on the other hand, can be taken with or without food, making it a more convenient option for patients.
<6> Study Results
The phase 3 randomised controlled trial included 1698 patients with type 2 diabetes who were inadequately controlled with metformin. The study was funded